Zoetis Inc. (NYSE:ZTS) today announced that it has extended until Oct.
30, 2013 at 5:00 p.m., New York City time, the expiration date of its
offer to exchange:
-
$400,000,000 aggregate principal amount of its unregistered 1.150%
Senior Notes due 2016 (the “2016 unregistered notes”) for a like
principal amount of its 1.150% Senior Notes due 2016 that have been
registered under the Securities Act of 1933;
-
$750,000,000 aggregate principal amount of its unregistered 1.875%
Senior Notes due 2018 (the “2018 unregistered notes”) for a like
principal amount of its 1.875% Senior Notes due 2018 that have been
registered under the Securities Act of 1933;
-
$1,350,000,000 aggregate principal amount of its unregistered 3.250%
Senior Notes due 2023 (the “2023 unregistered notes”) for a like
principal amount of its 3.250% Senior Notes due 2023 that have been
registered under the Securities Act of 1933; and
-
$1,150,000,000 aggregate principal amount of its unregistered 4.700%
Senior Notes due 2043 (the “2043 unregistered notes”) for a like
principal amount of its 4.700% Senior Notes due 2043 that have been
registered under the Securities Act of 1933.
The exchange offer had been scheduled to expire at 5:00 p.m., New York
City time, on Oct. 25, 2013. As of 5:00 p.m., New York City time, on
Oct. 25, 2013, all of the aggregate principal amount of the 2016
unregistered notes, 2018 unregistered notes and 2043 unregistered notes
had been tendered and not withdrawn, and $1,349,898,000 in aggregate
principal amount of the 2023 unregistered notes had been tendered and
not withdrawn.
The terms of the exchange offer and other information relating to Zoetis
are set forth in the prospectus dated Sept. 25, 2013. Copies of the
prospectus and the related letter of transmittal may be obtained from
Deutsche Bank Trust Company Americas, which is serving as the exchange
agent for the exchange offer. Deutsche Bank Trust Company Americas’s
address, telephone and facsimile number are as follows:
DB Services Americas, Inc.
Attention: Reorg. Department
5022
Gate Parkway, Suite 200
Jacksonville, FL 32256
DB.Reorg@db.com
Fax:
615-866-3889
Information: 877-843-9767
This communication shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be any
sale of securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under
the securities laws of any such jurisdiction. No offering of securities
shall be made except by means of an appropriate prospectus.
About Zoetis
Zoetis (zō-EH-tis) is the leading animal health company, dedicated to
supporting its customers and their businesses. Building on a 60-year
history as the animal health business of Pfizer, Zoetis discovers,
develops, manufactures and markets veterinary vaccines and medicines,
complemented by diagnostic products and genetic tests and supported by a
range of services. In 2012, the company generated annual revenues of
$4.3 billion. With approximately 9,300 employees worldwide at the
beginning of 2013, Zoetis has a local presence in approximately 70
countries, including 29 manufacturing facilities in 11 countries. Its
products serve veterinarians, livestock producers and people who raise
and care for farm and companion animals in 120 countries.
Forward-Looking Statements: This press release contains
forward-looking statements, which reflect Zoetis's current views with
respect to business plans or prospects, future operating or financial
performance, and other future events. These statements are not
guarantees of future performance. Forward-looking statements are subject
to risks and uncertainties. If one or more of these risks or
uncertainties materialize, or if management's underlying assumptions
prove to be incorrect, actual results may differ materially from those
contemplated by a forward-looking statement. Forward-looking statements
speak only as of the date on which they are made. Zoetis expressly
disclaims any obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise. A further list and description of risks, uncertainties
and other matters can be found in our Annual Report on Form 10-K for the
fiscal year ended December 31, 2012, including in the sections thereof
captioned “Forward-Looking Information and Factors That May Affect
Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on
Form 10-Q and in our Current Reports on Form 8-K. These filings and
subsequent filings are available online at www.sec.gov,
www.zoetis.com,
or on request from Zoetis.
Zoetis Inc.
Media Contacts:
Bill Price, 1-973-443-2742
william.price@zoetis.com
or
Elinore White, 1-973-443-2835
elinore.y.white@zoetis.com
or
Investor Contacts:
Dina Fede, 1-973-443-2969
or
John O’Connor, 1-973-822-7088